Related Experiment Video
Updated: Jun 2, 2026
13:17
Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
Published on: January 28, 2016
Human JC virus-like particles as a gene delivery vector.
Chi-Fang Chang1, Meilin Wang, Wei-Chih Ou
1National Chung Cheng University, Institute of Molecular Biology, 168, University Road, Min-Hsiung, Chiayi 621, Taiwan.
Expert Opinion on Biological Therapy
|May 11, 2011
Summary
Recombinant JC virus-like particles (VLPs) offer a cost-effective, gene-only delivery system for gene therapy. These engineered VLPs can efficiently target and transduce JC virus-susceptible cells without viral genetic material.
Area of Science:
- Virology
- Gene Therapy
- Biotechnology
Background:
- Recombinant JC virus-like particles (VLPs) are promising viral gene delivery vectors.
- VLPs are produced in large quantities affordably.
- Exogenous genes can be packaged into VLPs for delivery without viral genetic material.
Purpose of the Study:
- To review the development of gene delivery vectors using polyomavirus VLPs.
- To discuss the advantages and disadvantages of using JC VLPs for gene delivery.
Main Methods:
- Review of existing literature on polyomavirus VLP-based gene delivery.
- Discussion of the characteristics and potential applications of JC VLPs.
Main Results:
- JC VLPs are readily produced and easily engineered.
- Targeting is specific and achieved without viral genetic material.
- High-efficiency delivery of therapeutic genes or compounds to susceptible cells is possible.
Conclusions:
- Human JC VLPs represent a viable platform for gene therapy applications.
- Their ease of production, engineering, and specific targeting make them attractive for therapeutic development.
- Efficient delivery of therapeutic payloads to JC virus-susceptible cells is achievable.
